# Impact of Predischarge NT-proBNP on Treatment Optimisation in Acute Heart Failure

**Authors:** Marija Polovina, Milenko Tomić, Milica Janković, Danka Civrić, Andrea Stojićević, Stefan Stanković, Teodora Pejović, Mihajlo Viduljević, Gordana Krljanac, Milika Ašanin, Sanja Stanković, Petar M. Seferović

PMC · DOI: 10.3390/ijms27021028 · 2026-01-20

## TL;DR

High NT-proBNP levels at discharge in heart failure patients are linked to underuse of key medications, suggesting residual congestion affects treatment quality.

## Contribution

Shows that NT-proBNP trajectory and discharge levels predict underuse of guideline-directed medical therapies in acute heart failure.

## Key findings

- Higher discharge NT-proBNP is independently linked to lower use of key GDMT drugs.
- ΔNT-proBNP < 30% increases odds of GDMT underuse by 17%.
- Patients with poor NT-proBNP reduction are prescribed lower doses of titratable medications.

## Abstract

Residual congestion (RC) at discharge predicts adverse outcomes in heart failure with reduced ejection fraction (HFrEF). Its impact on the implementation of guideline-directed medical therapies (GDMT) remains unclear. N-terminal pro-B-type natriuretic peptide (NT-proBNP) trajectory during hospitalisation reflects RC and may be associated with GDMT implementation. The aim was to assess whether discharge NT-proBNP and a fall in NT-proBNP < 30% during hospitalisation (ΔNT-proBNP < 30%) predict GDMT underuse in acute HFrEF. In this prospective observational study, NT-proBNP was measured at hospital admission and 48–72 h before discharge. Provision of individual GDMT drug classes was assessed and GDMT underuse was defined as prescription of <3 key GDMT drug classes at discharge. 391 HFrEF patients (mean age, 69.9 ± 13.1years, 67.3% male) were included. ΔNT-proBNP < 30% was identified in 108 (27.6%). Higher discharge NT-proBNP was independently associated with lower likelihood of prescribing ACE-inhibitors, sacubitril/valsartan, eplerenone/spironolactone, or empagliflozin/dapagliflozin. ΔNT-proBNP < 30% was associated with 17% higher odds of GDMT underuse (95% confidence interval, 1.10–1.31, p < 0.001), regardless of clinical characteristics or in-hospital management. Patients with ΔNT-proBNP < 30% were discharged on lower doses of titratable GDMT medications. In-hospital NT-proBNP burden and trajectory, as markers of RC, are associated with GDMT underutilisation at discharge in acute HFrEF. Addressing RC may impact treatment quality in acute HFrEF.

## Linked entities

- **Chemicals:** sacubitril/valsartan (PubChem CID 24755620), eplerenone (PubChem CID 443872), spironolactone (PubChem CID 5833), empagliflozin (PubChem CID 11949646), dapagliflozin (PubChem CID 9887712)
- **Diseases:** heart failure (MONDO:0005252)

## Full-text entities

- **Diseases:** Heart Failure (MESH:D006333)
- **Chemicals:** eplerenone (MESH:D000077545), dapagliflozin (MESH:C529054), spironolactone (MESH:D013148), empagliflozin (MESH:C570240), valsartan (MESH:D000068756), sacubitril (MESH:C000717211), DeltaNT-proBNP (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12842275/full.md

---
Source: https://tomesphere.com/paper/PMC12842275